Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells.
Discover our mission
160
Employees in France and the United States
2
Preclinical laboratories dedicated to the development of alpha therapies
1
Industrial production platform for lead-212
2
Ongoing clinical trials
12
Patented inventions
+30%
growth of the radioligand therapy market

Our last news 

See More News
By clicking “I accept Cookies”, you agree with the cookies use to enhance site navigation, analyze site usage and compile statistics. To get more information, please read our Cookies Policy in the Legal Notice
I accept cookies I refuse cookies
Fermer
Fermer